InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,572.85
(
0.10%
)
US TECH 100
19,951.20
(
0.53%
)
Dow Jones
39,344.79
(
-0.08%
)
Brent Oil
85.40
(
-0.02%
)
Bitcoin
56,629.00
(
-0.14%
)
Post# of 46657
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

charthawk

Send PM Follow Ignore
Followers 187
Posts 27054
Boards Moderated 1
Alias Born 12/04/2003

charthawk

Re: Smoky81 post# 43986

Thursday, 02/09/2012 8:09:03 AM

Thursday, February 09, 2012 8:09:03 AM

Post# of 46657
7:55AM BioSante reports 'positive' LibiGel safety data review for Phase III program (BPAX) 0.84 : Co announced that the independent Data Monitoring Committee has completed the eighth unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects. The independent DMC has recommended that the LibiGel safety study should continue as per the FDA-agreed protocol, without modifications. LibiGel (testosterone gel) is in development for the treatment of female sexual dysfunction, specifically, hypoactive sexual desire disorder in menopausal women.



http://finance.yahoo.com/news/BioSante-Pharmaceuticals-bw-885355718.html?x=0

KRZNATE@

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up